Xeris Biopharma Holdings Inc reports results for the quarter ended in December - Earnings Summary

Xeris Biopharma Holdings

06/03/2024 14:41

* Xeris Biopharma Holdings Inc  XERS.OQ  reported a
quarterly
adjusted loss of 10 cents​​ per share for the quarter ended in
December, identical to the same quarter last year.  The mean
expectation of five analysts for the quarter was for a loss
of 10 cents per share. Wall Street expected results to range
from -13 cents to -7 cents per share.
    * Revenue rose 33.9% to $44.39 million from a year ago;
analysts
expected $43.55 million. 
    * Xeris Biopharma Holdings Inc's reported EPS for the
quarter was
a loss of 10 cents​.
    * The company reported a quarterly loss of $13.39 million.
    * Xeris Biopharma Holdings Inc shares had risen by 31.1%
this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.9%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Xeris Biopharma
Holdings Inc is $4.50 
This summary was machine generated from LSEG data March 6 at
02:40 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.10          -0.10          Met
 Sep. 30 2023      -0.12          -0.09          Beat
 Jun. 30 2023      -0.13          -0.14          Missed
 Mar. 31 2023      -0.17          -0.12          Beat